lobbying_activities: 2960927

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2960927	b9b09bc1-68f0-4182-b739-8c7f1022ae7f	Q1	FORBES-TATE	400976792	AMGEN USA, INC.	2023	first_quarter	MED	Issues related to Biosimilars; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2023-04-17T11:00:19-04:00